RxDoctor Payments DataLook up a doctor →

Edward Tavel, MD

Pain Medicine · Charleston, SCNPI 1508833468

Payments from drug & device makers

$1,384,840in general payments, 2019–2025

Across 243 payments — averaging $5698.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$759K
  • Ironwood Pharmaceuticals, Inc$214K
  • Regeneron$173K
  • AbbVie$85K
  • Mesoblast, Inc.$77K
  • Scilex Pharmaceuticals Inc.$21K
  • plus $55K from 19 others

What the payments were for

  • Travel & lodging$78132%
  • Food & beverage$1,65068%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,384,840 in reported general payments places this provider in the 95th percentile of 92 pain medicine providers in South Carolina.

See all pain medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$322,786
Medicare patients
631
Services billed
13,468

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate17$11,587
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen197$4,246
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen189$3,177
Gabapentin78$1,238
Tramadol Hcl ErTramadol Hcl12$997
Morphine Sulfate ErMorphine Sulfate40$938
Morphine Sulfate26$696
Cyclobenzaprine Hcl42$512
Tizanidine Hcl46$446
Pregabalin24$319
Alprazolam14$262
Tramadol Hcl52$244
Celecoxib25$199
Diclofenac Sodium12$182
Duloxetine Hcl14$181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$121$11,58717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 92 pain medicine providers in South Carolina.

Other pain medicine in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →